Caris Life Sciences (CAI) vs Quest Diagnostics (DGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Quest Diagnostics (DGX) has outperformed Caris Life Sciences (CAI) over the past year, gaining 24.8% versus a loss of 14.2%. Quest Diagnostics is the larger company by market cap ($25.05 billion vs $7.43 billion), about 3.4 times the size, while Caris Life Sciences is growing revenue faster (+97.0% vs +11.8%). On valuation, Quest Diagnostics trades at a lower forward P/E (18.8x vs 71.4x for Caris Life Sciences).
Quest Diagnostics pays a dividend yielding 1.46%, while Caris Life Sciences does not currently pay one. Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | DGX |
|---|---|---|
| Share price | $26.28 | $226.98 |
| Market cap | $7.43B | $25.05B |
| 1-day change | -3.03% | -0.04% |
| YTD return | +0.44% | +30.85% |
| 1-year return | -14.19% | +24.83% |
| 5-year return | — | +59.34% |
| P/E ratio (TTM) | 15.55 | 24.10 |
| Forward P/E | 71.37 | 18.83 |
| EPS (TTM) | $1.69 | $9.42 |
| Dividend yield | 0.00% | 1.46% |
| Annual dividend | $0.00 | $3.32 |
| Revenue (latest FY) | $812.03M | $11.04B |
| Revenue growth (YoY) | +96.97% | +11.78% |
| Net income (latest FY) | $-68.09M | $992.00M |
| Gross margin | — | 33.21% |
| Operating margin | 5.56% | 14.10% |
| Net margin | -8.38% | 8.99% |
| 52-week high | $33.65 | $248.84 |
| 52-week low | $14.19 | $171.18 |
| Distance from 52-week high | -21.90% | -8.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +10.65% | +9.29% |
| Average volume | 4.93M | 1.04M |
| Shares outstanding | 282.68M | 110.37M |
| Employees | 1,846 | 46,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Quest Diagnostics is about 3.4 times larger than Caris Life Sciences by market value ($25.05B vs $7.43B).
- DGX has outperformed CAI by 39.0 percentage points over the past year.
- Quest Diagnostics trades at a higher earnings multiple (24.1x vs 15.6x trailing P/E).
- Quest Diagnostics offers a meaningfully higher dividend yield (1.46% vs 0.00%).
- Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +11.78%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 46,000 employees
CAI vs DGX FAQ
Which is bigger, Caris Life Sciences or Quest Diagnostics?
Quest Diagnostics (DGX) is larger, with a market capitalization of $25.05B compared with $7.43B for Caris Life Sciences (CAI).
Which stock has performed better over the past year, CAI or DGX?
DGX returned +24.83% over the past 12 months, compared with -14.19% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or DGX?
CAI has the lower trailing P/E at 15.6, versus 24.1 for DGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Caris Life Sciences or Quest Diagnostics?
Quest Diagnostics pays a dividend yielding 1.46%, while Caris Life Sciences does not currently pay a regular dividend.
Are Caris Life Sciences and Quest Diagnostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.